|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM372068243 |
| 003 |
DE-627 |
| 005 |
20240830232745.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240509s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202402322
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1517.xml
|
| 035 |
|
|
|a (DE-627)NLM372068243
|
| 035 |
|
|
|a (NLM)38718226
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Kewei
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.07.2024
|
| 500 |
|
|
|a Date Revised 30.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Novel strategies to facilitate tumor-specific drug delivery and restore immune attacks remain challenging in overcoming the current limitations of chemoimmunotherapy. An antitumor chemoimmunotherapy system comprising bioorthogonal reaction-ready group tetrazine (TZ) modified with an anti-PD-L1 antibody (αPD-L1TZ) and TZ-activatable prodrug vinyl ether-doxorubicin (DOX-VE) for self-reinforced anti-tumor chemoimmunotherapy is proposed. The αPD-L1TZ effectively disrupts the PD-L1/PD-1 interaction and activates the DOX prodrug in situ through the bioorthogonal click reaction of TZ and VE. Conversely, the activated DOX upregulates PD-L1 on the surface of tumor cells, facilitating tumor accumulation of αPD-L1TZ and enhancing DOX-VE activation. Furthermore, the activated DOX-induced immunogenic cell death of tumor cells, substantially improving the response efficiency of αPD-L1 in an immune-suppressive tumor microenvironment. Thus, PD-L1 blocking and bioorthogonal in situ prodrug activation synergistically enhance the antitumor efficacy of the chemoimmunotherapy system. Therefore, the system significantly enhances αPD-L1 tumor accumulation and prodrug activation and induces a robust immunological memory effect to prevent tumor recurrence and metastasis. Thus, a feasible chemoimmunotherapy combination regimen is presented
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a bioorthogonal prodrug activation
|
| 650 |
|
4 |
|a cancer‐targeting chemotherapy
|
| 650 |
|
4 |
|a immunogenic cell death
|
| 650 |
|
4 |
|a self‐reinforced tumor targeting
|
| 650 |
|
4 |
|a tumor immune microenvironment
|
| 650 |
|
7 |
|a Prodrugs
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Jiang, Maolin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Tao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Ye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zong, Qingyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xu, Qing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ullah, Ihsan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yahui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Youyong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 30 vom: 02. Juli, Seite e2402322
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:30
|g day:02
|g month:07
|g pages:e2402322
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202402322
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 30
|b 02
|c 07
|h e2402322
|